Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
Símbolo de cotizaciónCUPR
Nombre de la empresaCuprina Holdings (Cayman) Ltd
Fecha de salida a bolsaApr 10, 2025
Director ejecutivoMr. Yong Qi (David) Quek
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 10
DirecciónBlock 1090
Ciudad
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísSingapore
Código postal169201
Teléfono6585127275
Sitio Webhttps://cuprina.com/
Símbolo de cotizaciónCUPR
Fecha de salida a bolsaApr 10, 2025
Director ejecutivoMr. Yong Qi (David) Quek
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos